AB014. OS03.04. Thymic epithelial tumors phenotype relies on MIR-145-5p epigenetic regulation

Teresa Bellissimo¹, Federica Ganci², Andrea Sacconi¹, Claudia Tito¹, Enzo Gallo³, Luciana De Angelis¹, Silvia Masciarelli¹, Daniele Diso⁴, Marco Anile¹, Vincenzo Petrozza⁵, Felice Giangaspero⁶, Edoardo Pescarmona³, Francesco Facciolo⁷, Gabriele Alessandrini², Federico Venuta⁴, Giovanni Blandino², Mirella Marino³, Francesco Fazi¹

¹Department of Anatomical, Histological, Forensic & Orthopaedic Sciences, Section of Histology & Medical Embryology, Sapienza University of Rome, Rome, Italy; ²Oncogenomic and Epigenetic Unit, ³Department of Pathology, Regina Elena National Cancer Institute, Rome, Italy; ⁴Department of Thoracic Surgery, Azienda Policlinico Umberto I, Sapienza University of Rome, Rome, Italy; ⁵Pathology Unit Icot, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; ⁶Department of Radiological, Oncological, and Pathological Science, Sapienza University of Rome, Rome, Italy; ⁷Thoracic Surgery, Regina Elena National Cancer Institute, Rome, Italy

Background: Thymic epithelial tumors (TETs) are rare tumors arising from the thymic epithelium, thymoma and thymic carcinoma being the most frequent subtypes. TET show a propensity to recur and to metastasize that is difficult to predict. A relevant advance in TET management could derive from a deeper molecular characterization of these neoplasms. In a previous multicenter study we identified a set of microRNA (miRNAs) differentially expressed in TETs and normal tissues (peritumoral thymi) from our biobanks performed by microarray analysis. MiR-145-5p role in TETs was evaluated in vitro, modulating its expression in a Thymic Carcinoma (TC1889) cell line. Epigenetic transcriptional regulation of miR-145-5p was examined by treating the TC1889 cell line with the HDAC inhibitor valproic acid (VPA).

Results: Basing on the identification of a 69-gene signature of miR-145-5p putative target mRNAs, whose expression was inversely correlated to that of miR-145-5p, we studied the expression of some of them in vitro upon overexpression of miR-145-5p; we observed that this resulted in the downregulation of the target genes, impacting on TETs cancerous phenotype. We also found that VPA treatment of TC1889 cells led to miR-145-5p up-regulation and concomitant down-regulation of miR-145-5p target genes and exhibited antitumor effects, as indicated by the induction of cell cycle arrest and by the reduction of cell viability, colony forming ability and migration capability. The importance of miR-145-5p up-regulation mediated by VPA is evidenced by the fact that hampering miR-145-5p activity by a LNA inhibitor reduced the impact of VPA treatment on cell viability and colony forming ability of TET cells. Finally, we observed that VPA was also able to enhance the response of TET cells to cisplatin and erlotinib.

Conclusions: Altogether our results suggest that the epigenetic regulation of miR-145-5p expression, as well as the modulation of its functional targets could be relevant players in tumor progression and treatment response in TETs.

Keywords: MicroRNA; gene expression profile; miR-145-5p; epigenetic regulation

Methods: mRNAs expression profiling of a cohort of fresh frozen TETs and normal tissues (peritumoral thymi) from our biobanks was performed by microarray analysis. MiR-145-5p role in TETs was evaluated in vitro, modulating its expression in a Thymic Carcinoma (TC1889) cell line. Epigenetic transcriptional regulation of miR-145-5p was examined by treating the TC1889 cell line with the HDAC inhibitor valproic acid (VPA).